Gland Pharma trades higher on getting USFDA`s approval for Sugammadex Injection
NiveshIQ
NSE: GLAND · Pharma
Gland Pharma Ltd.
₹2,543.70▲ ₹115.40 (+4.75%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on GLAND. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Gland Pharma Ltd.
Gland Pharma Limited is a leading Indian pharmaceutical company specializing in the manufacture and sale of injectable formulations across key global markets. The company's core business is driven by its research and development capabilities, which enable the synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. Its product portfolio spans various therapeutic categories, including anti-diabetic, anti-malarial, and anti-infectives. Gland Pharma has established a strong presence in the global market, with operations in the United States, Europe, Canada, Australia, New Zealand, and internationally. The company's recent financial performance has been impressive, with revenue of ₹6431 Cr and net income of ₹1027 Cr. Despit
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹5,664 Cr +228.70% | ₹5,617 Cr -0.80% | ₹6,431 Cr +14.50% |
| EBITDA Margin | 23.53% | 22.59% | 30.26% |
| Net Profit | ₹772.00 Cr +148.20% | ₹700.00 Cr -9.30% | ₹1,027 Cr +46.80% |
| EPS | ₹46.90 | ₹42.40 | ₹62.35 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Gland Pharma gets USFDA nod for generic sugammadex injection
Gland Pharma Gets USFDA Nod for Generic Sugammadex Injection
🔒
+ 3 more stories about Gland Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1, 743 Cr, PAT ₹367 Cr, EPS ₹22.26, EBITDA margin 35.8%. Growth context: revenue YoY +22.3%, PAT YoY +96.1%, revenue QoQ +2.8%, PAT QoQ +40.5%. Street verdict: beat, revenue surprise +1.2%, PAT surprise +7.2%.
Management commentary highlights the company's near-term growth drivers, including product launches, approvals, and ther...
FY26 (last completed FY): revenue ₹6, 431 Cr, PAT ₹1, 027 Cr, EBITDA margin 30.3%, EPS ₹62.35. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for GLAND
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track GLAND alongside your other holdings
Unlock full GLAND research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Gland Pharma Ltd.?
NiveshIQ detects active intelligence signals for Gland Pharma Ltd. (GLAND) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Gland Pharma Ltd.?
Gland Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹3,140,257.4L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.